drugset / Trial / NCT00657527

Evaluation of Effects of Rosuvastatin 40mg on Myocardial Ischemia in Subjects With Coronary Artery Disease

NCT00657527

Phase 3 Completed 280 enrolled AstraZeneca
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to determine whether treatment with 40mg of Rosuvastatin for 8 weeks will reduce the number of episodes of myocardial ischaemia suffered in subjects with coronary artery disease.

Timeline

Start
2001-12
Primary completion
Completion
2002-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Rosuvastatin Small molecule 40 mg